KRYSTAL BIOTECH INC

Krystal Biotech’s Q2 2026 earnings show $119M in VYJUVEK revenue, 95% margin, strong cash reserves, and expanding global reach for rare‑disease gene therapy.

Krystal Biotech, a Pittsburgh‑based biotech leader, is accelerating gene therapy breakthroughs for rare diseases, boasting a $5.72B market cap and high‑growth stock performance.

Krystal Biotech Inc is a pioneering biopharmaceutical company that is making a significant impact in the field of gene therapy, particularly in treating rare debilitating disorders.

Krystal Biotech Inc, a biopharmaceutical company focused on gene therapy for rare diseases, navigates a path of innovation and risk in the volatile biotechnology sector.

Krystal Biotech Inc’s first-quarter earnings fell short of expectations, but the company’s strategic global expansion efforts are expected to position it as a leader in the biotechnology sector and drive long-term growth.

Krystal Biotech, a biopharmaceutical company, will participate in upcoming scientific conferences to showcase its gene therapy platform for treating rare debilitating disorders.